Silence Therapeutics plc (SLNCF) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

Silence Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

Silence Therapeutics plc (SLNCF) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-05

• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.70%, a 18.39% increase from fiscal 2024.
• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 3.97%, a 10.38% decline from fiscal 2023.
• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.43%, a 24.09% increase from fiscal 2022.
• Silence Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.57%.